Amphawa Hospital
Samut Sakhon, Thailand
NCT Number: NCT04774016
The co-primary objectives of this study are: 1) to investigate the effect adding a synbiotic (combination of a pre-and probiotic) to iron-fortified follow-up formula (FUF) on iron bioavailability, and 2) to investigate the effect adding Human Milk Oligosaccharides (HMOs) to iron-fortified FUF on iron bioavailability in 10-14 month-old Thai children.
Looking for future studies?
Notify Me40 week–56 week
All sexes
Interventional
Not applicable
Samut Sakhon, Thailand
Iron stores of healthy, full-term neonates are supposed to cover iron needs for the first 4-6 months of life. After 6 months of age, requirements for absorbed iron are high, as infants need to build body iron stores and triple their body weight before the first year of life. Iron concentrations in mature breastmilk are low (~0.3 mg/L) and cannot adequately cover the high iron requirements of children between 6 and 24 months of age. Follow-up formulas (FUF) are fortified milk-based products intended for infants above 6 months of age and young children aged 1-3 years, and are widely used as a liquid part of the weaning diet to supplement the diet of young children with macro- and micronutrients. Prebiotics and probiotics are increasingly added to foods for infants and young children due to emerging evidence on possible health benefits. We recently showed that the addition of prebiotic galacto-oligosaccharides (GOS) to an iron-containing micronutrient powder increased iron absorption in Kenyan infants. To our knowledge, the effect of the combination of pre- and probiotics (synbiotic) or human milk oligosaccharides (HMOs) on iron absorption from an iron-fortified FUF has not been investigated.
Thai children (10-14 months old) will be assigned to receive FUF fortified with isotopically labelled iron as FeSO4 1) with synbiotic, 2) HMO, and 3) without added prebiotics as a reference, in random order. Besides the iron source and synbiotic or HMO, the test FUF will be identical in terms of macro- and micronutrient composition. For the secondary objectives of this study, which will have a single-group, before-after design, each infant will receive the test FUF with added synbiotic for 25 days on gut comfort and quality of life outcomes.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
An identical formula as test formulas fortified with 2.20 mg iron as FeSO4-58 and 0.05 mg native iron per serving (235 ml), but without added pre- or probiotic.
Test formula fortified with 2.20 mg iron as FeSO4-57 and 0.05 mg native iron per serving (235 ml) and added synbiotic.
Test formula fortified with 2.20 mg iron as FeSO4-54 and 0.05 mg native iron per serving (235 ml) and added HMOs.
Time frame: Measured 28 days after administration of last test formula
FIA from test formulas will be determined based on the shift of the iron isotope ratios in whole blood.
Time frame: Measured 14 days after administration of last test formula
FIA from test formulas will be determined based on the shift of the iron isotope ratios in whole blood.
Time frame: Measured 28 days after administration of last test formula
FIA from test formulas will be determined based on the shift of the iron isotope ratios in whole blood.
Time frame: Measured 14 days after administration of last test formula
FIA from test formulas will be determined based on the shift of the iron isotope ratios in whole blood.
Time frame: At baseline and last study visit (day 40)
Change in iron status biomarkers (Hb) from baseline until last study visit (day 40)
Time frame: At baseline and last study visit (day 40)
Change in iron status biomarkers (PF) from baseline until last study visit (day 40)
Time frame: At baseline and last study visit (day 40)
Change in iron status biomarkers (sTfR) from baseline until last study visit (day 40)
Time frame: At baseline and last study visit (day 40)
Change in CRP from baseline until last study visit (day 40)
Time frame: At baseline and last study visit (day 40)
Change in AGP from baseline until last study visit (day 40)
Time frame: At baseline and last study visit (day 40)
Change in GI tolerance based on caregiver-reported stool frequency (number of stools per day), consistency (on a scale from watery, runny, mushy soft, formed soft, hard, and difficult-to-pass stools (yes/no) from baseline until last study visit (day 40)
Time frame: At baseline and last study visit (day 40)
Change in gut comfort based on Gut Comfort Questionnaire to assess overall GI burden and individual GI symptoms/GI-related behaviours from baseline until last study visit (day 40)
Time frame: At baseline and last study visit (day 40)
Change in health-related quality of life, assessed by validated Infant and Toddler Quality of Life questionnaire from baseline until last study visit (day 40)
Time frame: At baseline and last study visit (day 40)
Change in gut microbiota composition and diversity between baseline and last study visit (day 40)
Time frame: At baseline and last study visit (day 40)
Change in fecal pH between baseline and last study visit (day 40)
Time frame: At baseline and last study visit (day 40)
Change in gut inflammation marker (calprotectin) between baseline and last study visit (day 40)
Time frame: At baseline and last study visit (day 40)
Change in gut integrity marker (serum intestinal fatty acid binding protein [I-FABP]) between baseline and last study visit (day 40)
Société des Produits Nestlé (SPN)
Industry
Iron Absorption From an Iron-fortified Follow-up Formula With and Without the Addition of a Synbiotic or Human Milk Oligosaccharides: a Stable Isotope Study in 10-14 Month-old Thai Children
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07143890
Iron Absorption, Iron Deficiencies
Zurich, Switzerland
View Trial DetailsNCT06650397
Callosities, Iron Absorption
Guatemala City, Departamento de Guatemala, Guatemala
View Trial DetailsNCT06629688
Diabetes Mellitus, Diabetes Mellitus Type 2
Zagreb, Croatia
View Trial DetailsNCT05266703
Anemia, Anemia, Hypochromic
Msambweni, Kenya
View Trial Details